News

The director of the Joseph Epstein Center for Emergency Medicine Research discussed whether years of experience causes variation in the way migraine is diagnosed and treated in an emergency department setting. [WATCH TIME: 2 minutes]

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed why MR fingerprinting holds significant clinical potential in epilepsy and epilepsy-related disorders.

The Centers for Medicare and Medicaid Services issued a proposed decision memo detailing the coverage criteria for patients with Alzheimer disease to be covered by the federal health insurance platform when administered aducanumab (Aduhelm; Biogen).

Mitzi Joi Williams, MD, founder and CEO of Joi Wellness Group Multiple Sclerosis Center, shared her thoughts on changes to the MS care model over the past year, as well as how the pandemic and telehealth have affected care for underrepresented populations.

The noninvasive vagus nerve stimulation device showed results consistent with what had been previously observed in the literature, with a particular benefit observed for those who have migraine with aura.

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed motivations behind creating the pen-and-paper test, as well as its digital companion. [WATCH TIME: 2 minutes]

Episode 17 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Clifton L. Gooch, MD, of the University of South Florida. [WATCH TIME: 7 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Roth, PhD. [LISTEN TIME: 12 minutes]

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]

Investigators partly attribute different trends in ischemic vs hemorrhagic strokes to differences in the development of acute therapeutic strategies over the 20-year study period.

Mortality remained elevated even after 20 years poststroke, highlighting the importance of long-term follow-up in this patient population.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided background on the momentum behind MR fingerprinting and its potential in epilepsy care. [WATCH TIME: 3 minutes]

Daridorexant, which will be marketed as Quviviq, will be available later this year after being scheduled by the US Drug Enforcement Administration.

The founder and CEO of Joi Wellness Group Multiple Sclerosis Center explained her reasoning as to why she hopes telemedicine is here to stay. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The association of feelings of worse performance depended on age, with a higher frequency of amyloid positivity at older ages and a lower frequency at lower ages.

Douglas Scharre, MD, discussed the key findings from a recent study evaluating the Self-Administered Gerocognitive Exam and its application for at-risk populations.

Discussing the willingness to share data during the pandemic, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke to the positive effect of collaboration in the MS field. [WATCH TIME: 2 minutes]

This now-validated tool showed an ability to accurately identify focal seizure-onset zone, which may help epilepsy centers when faced with the challenge of whether a patient should undergo implantation.

According to the study, which assessed the EAT-Lancet diet and Alternate Health Eating Index-2010 in more than 2000 patients, dietary pattern has a distinct association with different stroke subtypes.

Douglas Scharre, MD, provided an overview of the pen-and-paper and digital versions of the test, which do not require an administrator.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center commented on the effect of the pandemic on needs for underrepresented populations in the multiple sclerosis space, as well as the pros and cons of telehealth. [WATCH TIME: 3 minutes]

Patients treated with valbenazine demonstrated favorable outcomes on all secondary outcomes over placebo, as well showed no new safety signals.

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester offered an extensive overview of 3 monoclonal antibodies in development for Alzheimer disease. [WATCH TIME: 9 minutes]

The Jazz Pharmaceuticals’ product, which was FDA approved in August 2021, demonstrated clinically meaningful differences compared with placebo on several secondary end points, including impression of change scales and various and questionnaires.

The authors noted that future studies should investigate this association to identify patients with obstructive sleep apnea who are at risk of potential cognitive decline and adverse health function.

Investigators assert there is still room for improvement to further minimize exposure, as the treatment was used in a relevant number of pregnancies in 2016.